The decision was made in response to recent reports related to additional events identified in a cohort of volunteers in a safety study involving the drug. The decision to discontinue the development programs was made in conjunction with representatives from the Data Safety Monitoring Board, the Governance Council for the African sleeping sickness grant for the pneumocystis pneumonia (PCP) study. The company’s licensing partners, Par Pharmaceutical Companies and BioAlliance Pharma, remain in full support of the company.
Eric Sorkin, chairman and CEO of Immtech said: “We will continue to focus our efforts on developing the compounds in our library, pursuing licensing agreements and commercial opportunities and further expanding our growth opportunities in China and in other global markets.”